Biblio Discovery — Demo Discovery Service

8 hasil untuk "John C. Harding"

Menampilkan 1–8 · 0,28 detik · RSS

  1. Artikel Jurnal Teks lengkap

    IL-15 deficient tax mice reveal a role for IL-1α in tumor immunity.

    Daniel A Rauch; John C Harding; Lee Ratner

    PLoS ONE, Vol. 9 No. 1 · 2014 · Inggris · DOAJ Scopus

    IL-15 is recognized as a promising candidate for tumor immunotherapy and has been described as both a promoter of cancer and a promoter of anti-cancer immunity. IL-15 was discovered in cells transformed by HTLV-1, the etiologic agent of adult T cell leukemia/lymphoma (ATL) and the human retrovirus…

    Juga tersedia di: PLOS

  2. Artikel Jurnal Teks lengkap

    Targeting NF-κB with Nanotherapy in a Mouse Model of Adult T-Cell Leukemia/Lymphoma

    Daniel A. Rauch; John C. Harding; Lee Ratner dkk.

    Nanomaterials, Vol. 11 No. 6 · 2021 · Inggris · DOAJ Scopus

    Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, clonal malignancy of mature T cells caused by human T-cell leukemia virus type 1. Although it is a rare tumor type, it serves as an excellent model of a virus driven process that transforms cells and engenders a highly malignant tumor that is…

  3. Artikel Jurnal

    Adult T-Cell Leukemia-Lymphoma Presenting Concurrently with Myelopathy

    Sneha Poondru; Ancy Joseph; John C. Harding dkk.

    Case Reports in Oncology, Vol. 15 No. 3 · 2022 · Inggris · DOAJ Scopus

    Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus. Of the approximate ten to twenty million people currently infected worldwide, 4–9% of infected individuals develop adult T-cell leukemia/lymphoma (ATLL) or HTLV-associated myelopathy/tropical spastic paresis (HAM/TSP) in their…

  4. Artikel Jurnal

    Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma

    Daniel A. Rauch; Sydney L. Olson; John C. Harding dkk.

    Retrovirology, Vol. 17 No. 1 · 2020 · Inggris · DOAJ Scopus

    Abstract Background Adult T-cell leukemia lymphoma (ATLL) is a chemotherapy-resistant malignancy with a median survival of less than one year that will afflict between one hundred thousand and one million individuals worldwide who are currently infected with human T-cell leukemia virus type 1…

  5. Artikel Jurnal Teks lengkap

    Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice

    Qingyu Zhou; John C. Harding; Ping Fan dkk.

    Nanomaterials, Vol. 14 No. 21 · 2024 · Inggris · DOAJ Scopus

    Nanomedicine holds great potential for revolutionizing medical treatment. Ongoing research and advancements in nanotechnology are continuously expanding the possibilities, promising significant advancements in healthcare. To fully harness the potential of nanotechnology in medical applications, it…

  6. Artikel Jurnal Teks lengkap

    The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice

    Daniel A. Rauch; Michelle A. Hurchla; John C. Harding dkk.

    PLoS ONE, Vol. 5 No. 12 · 2010 · Inggris · PLOS Scopus

    The ARF tumor suppressor regulates p53 as well as basic developmental processes independent of p53, including osteoclast activation, by controlling ribosomal biogenesis. Here we provide evidence that ARF is a master regulator of bone remodeling and osteosarcoma (OS) development in mice. Arf-/- mice…

    Juga tersedia di: DOAJ